In the Phase 1b dose expansion part of the study, heavily pretreated patients with metastatic melanoma were treated with IMA203. Data from the study showed a significant positive shift in median ...

Immatics (IMTX) has released an update. Immatics has reported promising updated Phase 1b clinical data for its ACTengine ...

Zealand Pharma is working on the next-gen weight-loss treatment. Its Petrelintide showed promising results in a Phase 1b ...

An experimental immunotherapy candidate targets toxic species of alpha-synuclein and was well tolerated in an ongoing, ...

A phase 1b trial showed promising results among patients with relapsed or refractory chronic lymphocytic leukemia.

Tempest Therapeutics enters a Phase 3 trial for its liver cancer drug amezalpat, in collaboration with Roche. The trial ...

Immatics announced updated Phase 1b data for its IMA203 therapy in metastatic melanoma. A deep tumor reduction response was observed in about half of the patients, with positive survival benefits ...

Immatics has vaulted into phase 3 on the strength of early-stage data. The biotech is gearing up to start a pivotal trial of ...

(RTTNews) - Viking Therapeutics, Inc. (VKTX), Wednesday announced positive data from Phase 1b study of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD). X-ALD is a rare and often fatal ...

CLD-101 is a novel stem cell-based treatment that delivers oncolytic viruses to tumors, which may benefit patients with newly ...

Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...